Westin, Jason R <br/><br/>
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.  [electronic resource] 

 -  The Lancet. Oncology  Jan 2014 
 - 69-77 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(13)70551-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Female<br/>Humans<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Middle Aged<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Recurrence<br/>Rituximab